Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000795475 | SCV000934939 | uncertain significance | Bifunctional peroxisomal enzyme deficiency; Perrault syndrome | 2022-12-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt HSD17B4 protein function. ClinVar contains an entry for this variant (Variation ID: 642085). This variant has not been reported in the literature in individuals affected with HSD17B4-related conditions. This variant is present in population databases (rs763390035, gnomAD 0.006%). This sequence change replaces valine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 567 of the HSD17B4 protein (p.Val567Ala). |
Ambry Genetics | RCV002537001 | SCV003720107 | uncertain significance | Inborn genetic diseases | 2021-07-14 | criteria provided, single submitter | clinical testing | The c.1700T>C (p.V567A) alteration is located in exon 20 (coding exon 20) of the HSD17B4 gene. This alteration results from a T to C substitution at nucleotide position 1700, causing the valine (V) at amino acid position 567 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001274462 | SCV001458672 | uncertain significance | Bifunctional peroxisomal enzyme deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |